An explosion of hefty – and, in some cases, repeat – continuation fund processes underscores the increasing maturation of Europe’s secondaries landscape.

Though the healthcare sector’s headline deal values may look healthy enough, policy upheavals in the US and ongoing fundraising pain may be weakening its underlying condition.

LPs in drawdown funds are right to question how their exposure to investments will be affected by semi-liquid capital investing in the same deals.